ANCEF
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Oct 1973
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ANCEF is a cephalosporin antibiotic approved in 1973 for parenteral use. The generic name is cefazolin. It is used to treat bacterial infections across multiple indications including surgical prophylaxis and systemic infections.
LOE Approaching
As a mature injectable antibiotic approaching loss of exclusivity, the brand team is likely small and focused on defensive positioning against generic competition and newer alternatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
ANCEF positions offer limited career growth given its mature lifecycle and approaching loss of exclusivity. Roles are primarily defensive and operationally focused on managing generic competition and maintaining customer relationships in hospital and surgical settings.
Brand ManagerField Sales Representative
Worked on ANCEF at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.